Difference between revisions of "Part:BBa K4165195"

(Dry lab)
 
Line 15: Line 15:
 
===Dry lab===
 
===Dry lab===
 
<p style=" font-weight: bold; font-size:14px;"> Modeling </p>
 
<p style=" font-weight: bold; font-size:14px;"> Modeling </p>
The peptide was modeled by several software (Alphafold - Apptest - Pepfold) and the best model from Apptest.
+
The peptide was modeled by several software (Alphafold - Apptest - Pepfold) and the best model was obtained from Apptest.
  
 
<html>
 
<html>
Line 22: Line 22:
  
 
                                 Figure 1.: Amyloid-beta (34-42) top model visualized by pymol.
 
                                 Figure 1.: Amyloid-beta (34-42) top model visualized by pymol.
 
 
 
  
 
===References===
 
===References===

Latest revision as of 19:55, 11 October 2022


Amyloid beta peptide 15 (Aβ 34-42)

This part encodes a part of the Amyloid 𝛽 fragment (34-42) which has the ability to bind to A𝛽 plaques inside the brain.


Usage and Biology

Segments of amyloid beta fibrils are widely used as a recognition sequence for amyloid beta plaques inside the brain, this is due to the homotypic interactions in the C-terminus of fibrils. This peptide starts from amino acid 29 to 42 of the fibril. This binding peptide starts from amino acid 34 to 42.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


Dry lab

Modeling

The peptide was modeled by several software (Alphafold - Apptest - Pepfold) and the best model was obtained from Apptest.

                               Figure 1.: Amyloid-beta (34-42) top model visualized by pymol.

References

1-Zhao, Y., Cai, J., Liu, Z., Li, Y., Zheng, C., Zheng, Y., ... & Liu, Y. (2018). Nanocomposites inhibit the formation, mitigate the neurotoxicity, and facilitate the removal of β-amyloid aggregates in Alzheimer’s disease mice. Nano letters, 19(2), 674-683.